Logo image of IDEX.OL

IDEX BIOMETRICS ASA (IDEX.OL) Stock Fundamental Analysis

OSL:IDEX - NO0013536078 - Common Stock

2.73 NOK
-0.03 (-1.09%)
Last: 9/5/2025, 7:00:00 PM
Fundamental Rating

1

Overall IDEX gets a fundamental rating of 1 out of 10. We evaluated IDEX against 53 industry peers in the Electronic Equipment, Instruments & Components industry. IDEX has a bad profitability rating. Also its financial health evaluation is rather negative. IDEX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IDEX has reported negative net income.
In the past year IDEX has reported a negative cash flow from operations.
IDEX had negative earnings in each of the past 5 years.
In the past 5 years IDEX always reported negative operating cash flow.
IDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFIDEX.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

The Return On Assets of IDEX (-100.76%) is worse than 92.45% of its industry peers.
The Return On Equity of IDEX (-931.96%) is worse than 90.57% of its industry peers.
Industry RankSector Rank
ROA -100.76%
ROE -931.96%
ROIC N/A
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
IDEX.OL Yearly ROA, ROE, ROICIDEX.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

IDEX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDEX.OL Yearly Profit, Operating, Gross MarginsIDEX.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

1

2. Health

2.1 Basic Checks

IDEX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, IDEX has more shares outstanding
Compared to 5 years ago, IDEX has more shares outstanding
The debt/assets ratio for IDEX has been reduced compared to a year ago.
IDEX.OL Yearly Shares OutstandingIDEX.OL Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
IDEX.OL Yearly Total Debt VS Total AssetsIDEX.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

IDEX has an Altman-Z score of -3.92. This is a bad value and indicates that IDEX is not financially healthy and even has some risk of bankruptcy.
IDEX has a Altman-Z score of -3.92. This is amonst the worse of the industry: IDEX underperforms 88.68% of its industry peers.
A Debt/Equity ratio of 1.75 is on the high side and indicates that IDEX has dependencies on debt financing.
IDEX's Debt to Equity ratio of 1.75 is on the low side compared to the rest of the industry. IDEX is outperformed by 86.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.75
Debt/FCF N/A
Altman-Z -3.92
ROIC/WACCN/A
WACC8.14%
IDEX.OL Yearly LT Debt VS Equity VS FCFIDEX.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

IDEX has a Current Ratio of 1.67. This is a normal value and indicates that IDEX is financially healthy and should not expect problems in meeting its short term obligations.
IDEX has a Current ratio of 1.67. This is comparable to the rest of the industry: IDEX outperforms 52.83% of its industry peers.
IDEX has a Quick Ratio of 1.67. This is a bad value and indicates that IDEX is not financially healthy enough and could expect problems in meeting its short term obligations.
IDEX has a worse Quick ratio (0.47) than 88.68% of its industry peers.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 0.47
IDEX.OL Yearly Current Assets VS Current LiabilitesIDEX.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 92.99% over the past year.
IDEX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.72%.
The Revenue has been growing by 14.73% on average over the past years. This is quite good.
EPS 1Y (TTM)92.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
Revenue 1Y (TTM)-87.72%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-79.49%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IDEX.OL Yearly Revenue VS EstimatesIDEX.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B
IDEX.OL Yearly EPS VS EstimatesIDEX.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2025 0 -20 -40 -60 -80 -100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

IDEX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
IDEX is valuated cheaply with a Price/Forward Earnings ratio of 5.26.
Based on the Price/Forward Earnings ratio, IDEX is valued cheaply inside the industry as 94.34% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.69. IDEX is valued rather cheaply when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 5.26
IDEX.OL Price Earnings VS Forward Price EarningsIDEX.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDEX.OL Per share dataIDEX.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IDEX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IDEX BIOMETRICS ASA

OSL:IDEX (9/5/2025, 7:00:00 PM)

2.73

-0.03 (-1.09%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryElectronic Equipment, Instruments & Components
Earnings (Last)08-27 2025-08-27/bmo
Earnings (Next)11-13 2025-11-13
Inst Owners1.4%
Inst Owner ChangeN/A
Ins Owners0.62%
Ins Owner ChangeN/A
Market Cap47.90M
Analysts82.86
Price Target1148.1 (41954.95%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9899.97%
PT rev (3m)8571.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.26
P/S 17.73
P/FCF N/A
P/OCF N/A
P/B 5.18
P/tB 11.95
EV/EBITDA N/A
EPS(TTM)-6.04
EYN/A
EPS(NY)0.52
Fwd EY19.02%
FCF(TTM)-5.63
FCFYN/A
OCF(TTM)-5.63
OCFYN/A
SpS0.15
BVpS0.53
TBVpS0.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -100.76%
ROE -931.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-119.85%
ROA(5y)-118.87%
ROE(3y)-228.17%
ROE(5y)-196.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 1.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 0.47
Altman-Z -3.92
F-Score2
WACC8.14%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-87.72%
Revenue growth 3Y-33.35%
Revenue growth 5Y14.73%
Sales Q2Q%-79.49%
Revenue Next Year49.24%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1659.05%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y67.63%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y67.27%
OCF growth 3YN/A
OCF growth 5YN/A